Amgen Has US Rituximab Nod - But No RA Indication
Riabni Biosimilar Rival To Rituxan Seeks To Compete With Price Discount
Amgen has received FDA approval and revealed launch plans for its Riabni rituximab rival to Rituxan, setting a price discount in line with Pfizer’s Ruxience version. However, the biosimilar has not been approved for the rheumatoid arthritis indication that is enjoyed by Teva and Celltrion’s higher-priced Truxima version.
